Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

A. Charehbili, S. van de Ven, V. T. H. B. M. Smit, E. Meershoek-Klein Kranenbarg, N. A. T. Hamdy, H. Putter, J. B. Heijns, L. J. C. van Warmerdam, L. Kessels, M. Dercksen, M. J. Pepels, E. Maartense, H. W. M. van Laarhoven, B. Vriens, M. N. Wasser, A. E. van Leeuwen-Stok, G. J. Liefers, C. J. H. van de Velde, J. W. R. Nortier, J. R. Kroep*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Web of Science)
Original languageEnglish
Pages (from-to)998-1004
JournalAnnals of Oncology
Issue number5
Publication statusPublished - May 2014


  • neoadjuvant chemotherapy
  • zoledronic acid
  • bisphosphonates
  • menopausal status

Cite this